[go: up one dir, main page]

WO2024227047A3 - Arn guide modifié - Google Patents

Arn guide modifié Download PDF

Info

Publication number
WO2024227047A3
WO2024227047A3 PCT/US2024/026601 US2024026601W WO2024227047A3 WO 2024227047 A3 WO2024227047 A3 WO 2024227047A3 US 2024026601 W US2024026601 W US 2024026601W WO 2024227047 A3 WO2024227047 A3 WO 2024227047A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified
target
guide rna
modified guide
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/026601
Other languages
English (en)
Other versions
WO2024227047A2 (fr
Inventor
Brian CAFFERTY
Ho YAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beam Therapeutics Inc
Original Assignee
Beam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beam Therapeutics Inc filed Critical Beam Therapeutics Inc
Priority to CN202480027660.0A priority Critical patent/CN121079412A/zh
Priority to AU2024261906A priority patent/AU2024261906A1/en
Publication of WO2024227047A2 publication Critical patent/WO2024227047A2/fr
Publication of WO2024227047A3 publication Critical patent/WO2024227047A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des molécules d'ARNg modifiées, des compositions et des procédés pour l'édition génique et la modification génomique spécifiques à un site, telles que le clivage d'ADN, et l'activation ou la répression de gènes. Les présents ARN guides modifiés ont une structure secondaire modifiée (par exemple, une longue tige supérieure et une structure en épingle à cheveux modifiée), qui cible la séquence d'ADN cible spécifiquement avec une activité hors cible réduite.
PCT/US2024/026601 2023-04-28 2024-04-26 Arn guide modifié Pending WO2024227047A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202480027660.0A CN121079412A (zh) 2023-04-28 2024-04-26 经修饰的指导rna
AU2024261906A AU2024261906A1 (en) 2023-04-28 2024-04-26 Modified guide rna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363462873P 2023-04-28 2023-04-28
US63/462,873 2023-04-28

Publications (2)

Publication Number Publication Date
WO2024227047A2 WO2024227047A2 (fr) 2024-10-31
WO2024227047A3 true WO2024227047A3 (fr) 2024-12-19

Family

ID=91334660

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/026601 Pending WO2024227047A2 (fr) 2023-04-28 2024-04-26 Arn guide modifié

Country Status (3)

Country Link
CN (1) CN121079412A (fr)
AU (1) AU2024261906A1 (fr)
WO (1) WO2024227047A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020051562A2 (fr) 2018-09-07 2020-03-12 Beam Therapeutics Inc. Compositions et procédés d'amélioration de l'édition de base

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089433A1 (fr) * 2014-12-03 2016-06-09 Agilent Technologies, Inc. Arn guide comportant des modifications chimiques
WO2017044776A1 (fr) * 2015-09-10 2017-03-16 Texas Tech University System Arn de guidage unique (sgrna) présentant une efficacité d'inactivation améliorée
WO2017068377A1 (fr) * 2015-10-23 2017-04-27 Silence Therapeutics (London) Ltd Arn guides modifiés, méthodes et utilisations
WO2018107028A1 (fr) * 2016-12-08 2018-06-14 Intellia Therapeutics, Inc. Arn guides modifiés
WO2019126037A1 (fr) * 2017-12-19 2019-06-27 City Of Hope Arncr transactivateurs et arng modifiés et leurs utilisations
WO2019183000A1 (fr) * 2018-03-19 2019-09-26 University Of Massachusetts Arn guides modifiés pour l'édition de génome au moyen de crispr
WO2021113494A1 (fr) * 2019-12-03 2021-06-10 Beam Therapeutics Inc. Arn guide synthétique, compositions, procédés et utilisations de ceux-ci
WO2022248454A1 (fr) * 2021-05-27 2022-12-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouveaux arng crispr
WO2023245141A2 (fr) * 2022-06-15 2023-12-21 Beam Therapeutics Inc. Compositions et procédés pour réduire l'activation du complément
WO2024006772A2 (fr) * 2022-06-27 2024-01-04 Beam Therapeutics Inc. Éditeurs de base d'adénosine désaminase et leurs procédés d'utilisation
WO2024042489A1 (fr) * 2022-08-25 2024-02-29 LifeEDIT Therapeutics, Inc. Modification chimique d'arn guides avec un acide nucléique verrouillé pour l'édition de gènes à médiation par nucléase guidée par l'arn

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043060A (en) 1996-11-18 2000-03-28 Imanishi; Takeshi Nucleotide analogues
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
SI20474A (sl) 1998-05-26 2001-08-31 Icn Pharmaceuticals, Inc. Novi nukleozidi, ki imajo bicikličen sladkorni del
CA2368135C (fr) 1999-03-18 2010-06-08 Exiqon A/S Analogues de xylo-lna
WO2000056746A2 (fr) 1999-03-24 2000-09-28 Exiqon A/S Synthese perfectionnee de [2.2.1]bicyclo-nucleosides
PT1178999E (pt) 1999-05-04 2007-06-26 Santaris Pharma As Análogos de l-ribo-lna
AU5429000A (en) 1999-06-25 2001-01-31 Sankyo Company Limited Novel bicyclonucleoside derivatives
JP4151751B2 (ja) 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
CA2504694C (fr) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Composes oligomeres renfermant un substitut de sucre polycyclique et compositions intervenant dans la modulation genique
JP4731324B2 (ja) 2003-08-28 2011-07-20 武 今西 Ｎ−ｏ結合性架橋構造型新規人工核酸
WO2005027962A1 (fr) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides et composes d'oligomeres
ES2516815T3 (es) 2006-01-27 2014-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en la posición 6
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
WO2008150729A2 (fr) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. Analogues d'acides nucléiques bicycliques pontés par aminométhylène n-substitué
EP2173760B2 (fr) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Analogues d'acide nucléique bicyclique carbocylique
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
KR20230158531A (ko) 2021-03-23 2023-11-20 빔 테라퓨틱스, 인크. 신규 crispr 효소, 방법, 시스템 및 그 용도
KR20240116827A (ko) 2021-12-17 2024-07-30 빔 테라퓨틱스, 인크. 신규한 crispr 효소, 방법, 시스템 및 이의 용도

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089433A1 (fr) * 2014-12-03 2016-06-09 Agilent Technologies, Inc. Arn guide comportant des modifications chimiques
WO2017044776A1 (fr) * 2015-09-10 2017-03-16 Texas Tech University System Arn de guidage unique (sgrna) présentant une efficacité d'inactivation améliorée
WO2017068377A1 (fr) * 2015-10-23 2017-04-27 Silence Therapeutics (London) Ltd Arn guides modifiés, méthodes et utilisations
WO2018107028A1 (fr) * 2016-12-08 2018-06-14 Intellia Therapeutics, Inc. Arn guides modifiés
WO2019126037A1 (fr) * 2017-12-19 2019-06-27 City Of Hope Arncr transactivateurs et arng modifiés et leurs utilisations
WO2019183000A1 (fr) * 2018-03-19 2019-09-26 University Of Massachusetts Arn guides modifiés pour l'édition de génome au moyen de crispr
WO2021113494A1 (fr) * 2019-12-03 2021-06-10 Beam Therapeutics Inc. Arn guide synthétique, compositions, procédés et utilisations de ceux-ci
WO2022248454A1 (fr) * 2021-05-27 2022-12-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouveaux arng crispr
WO2023245141A2 (fr) * 2022-06-15 2023-12-21 Beam Therapeutics Inc. Compositions et procédés pour réduire l'activation du complément
WO2024006772A2 (fr) * 2022-06-27 2024-01-04 Beam Therapeutics Inc. Éditeurs de base d'adénosine désaminase et leurs procédés d'utilisation
WO2024042489A1 (fr) * 2022-08-25 2024-02-29 LifeEDIT Therapeutics, Inc. Modification chimique d'arn guides avec un acide nucléique verrouillé pour l'édition de gènes à médiation par nucléase guidée par l'arn

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAO YIN ET AL: "Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing", NATURE BIOTECHNOLOGY, vol. 35, no. 12, 13 November 2017 (2017-11-13), New York, pages 1179 - 1187, XP055484407, ISSN: 1087-0156, DOI: 10.1038/nbt.4005 *

Also Published As

Publication number Publication date
WO2024227047A2 (fr) 2024-10-31
CN121079412A (zh) 2025-12-05
AU2024261906A1 (en) 2025-10-23

Similar Documents

Publication Publication Date Title
WO2019103442A3 (fr) Composition d'édition génomique utilisant un système crispr/cpf1 et son utilisation
AR107621A2 (es) Plantas de algodón con tolerancia a herbicidas y métodos para identificarlas
WO2008063203A3 (fr) Compositions et méthodes de silençage efficace de gènes dans des végétaux
WO2004081228A3 (fr) Profilage de l'expression genique en temps reel
EP3699280A3 (fr) Nouveaux systèmes cas9 et procédés d'utilisation
PL2357230T3 (pl) Modyfikacje RNA skutkujące ulepszoną stabilnością transkryptu i skutecznością translacji
NZ597299A (en) Use of a cas gene in combination with CRISPR repeats for modulating resistance in a cell
WO2008154695A8 (fr) Procédé permettant d'améliorer la résistance à un stress de plantes et de leurs matériaux
WO2007014275A3 (fr) Integration et expression ciblees de sequences d'acides nucleiques exogenes
WO2004035765A3 (fr) Structures et constructions d'arn a double brin et procedes pour leur generation et leur utilisation
WO2004011624A3 (fr) Structures et constructions d'arn a double brin, et leurs procedes de production et d'utilisation
WO2004037977A3 (fr) Utilisation de nucleases chimeres pour stimuler le ciblage de genes
DE50311850D1 (de) Konstrukte und verfahren zur regulation der genexpression
MX2021004455A (es) Composiciones y métodos para administrar transgenes.
MX2020001998A (es) Tecnología de alteración específica de secuencia objetivo utilizando reconocimiento de objetivos del nucleotído.
CN115768886A (zh) 一种基因组编辑系统及方法
WO2007089732A3 (fr) Amélioration des niveaux et/ou de la durabilité de l'expression génique à base d'adn
WO2024227047A3 (fr) Arn guide modifié
ATE452187T1 (de) Methode zur isolation von nukleinsäuren
CN106103712B (zh) 一种高效基因克隆方法及其应用
US20190218533A1 (en) Genome-Scale Engineering of Cells with Single Nucleotide Precision
KR102648886B1 (ko) 세포의 유전체에서 표적 핵산을 변형시키는 방법
ATE420975T1 (de) Methode zur linearen nicht-selektiven amplifikation von nukleinsäuren
US9944966B2 (en) Method for production of single-stranded macronucleotides
WO2022243748A3 (fr) Procédés d'enrichissement d'acide nucléique ciblé, identification de hors cible et évaluation de l'efficacité d'édition de gène

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24730119

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024261906

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2024261906

Country of ref document: AU

Date of ref document: 20240426

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2024730119

Country of ref document: EP